It suggests that immunotherapy using IL-4 or immune-checkpoint inhibitors may have lower therapeutic effects on the acral melanoma than non-acral melanoma, however, further research is needed on this issue. The gene discussed is IL4; the disease is acral lentiginous melanoma.